How calcium signaling affects the clearance of harmful proteins in Alzheimer's disease
Official title: Regulation of Neuronal Clearance Pathways via Nuclear Calcium Signaling in Alzheimer's Disease
Funded at Rutgers the State Univ of Nj Newark · NIH-10624820 · Data updated 2026-11-12
This study is looking at how problems with calcium signals in brain cells might cause harmful proteins to build up in Alzheimer's disease, and it hopes to find new ways to help keep brain cells healthy, which could lead to better treatments for patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Rutgers the State Univ of Nj Newark NIH-funded |
| Lab location | 1 site (Newark, United States) |
| Project start | September 1, 2019 |
| Project end | May 31, 2026 |
| Funding year | 2023 |
| Award (this year) | $440,788 |
| NIH project number | 5R01AG062475-05 |
| Project ID | NIH-10624820 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are adults diagnosed with Alzheimer's disease or those at risk due to genetic factors.
✕Less likely to help
Patients with other forms of dementia unrelated to Alzheimer's disease may not benefit from this research.
What this research studies
This research investigates how disruptions in calcium signaling within neurons may lead to the accumulation of toxic proteins associated with Alzheimer's disease. By focusing on the role of nuclear calcium levels and their impact on the autolysosomal system, the study aims to uncover mechanisms that contribute to neurodegeneration. The researchers will explore how specific genetic mutations related to Alzheimer's affect these processes and may identify new pathways for promoting neuronal health. Patients may benefit from insights that could lead to novel therapeutic strategies targeting these pathways.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that enhance the clearance of neurotoxic proteins in Alzheimer's patients, potentially slowing disease progression.
How similar studies have gone: Previous studies have shown promising results in targeting cellular clearance mechanisms in neurodegenerative diseases, suggesting that this approach may yield beneficial outcomes.
Where this research is happening
-
Rutgers the State Univ of Nj Newark
Newark, United States Active
Researchers
- Principal investigator: Friedman, Wilma J — Rutgers the State Univ of Nj Newark
- Study coordinator: Friedman, Wilma J
Related research
Other NIH-funded projects on the same topics.
-
Understanding how brain activity changes may drive Alzheimer’s disease progression in a mouse model
Researchers are testing how changes in brain signals and protein cleanup processes affect the development of Alzheimer’s disease in mice.
-
Thiamine-boosting therapy for Alzheimer’s: understanding how benfotiamine may reduce harmful AGE in DP patients
A medication-based approach using high-dose vitamin B1 (benfotiamine) is studied to help people with Alzheimer's by reducing harmful sugar-related molecules.
-
Non-invasive tears biomarker for early Alzheimer's in LMICs
A low-cost, tear-based biomarker approach aims to detect early Alzheimer’s disease in older adults in Peru and similar settings.
-
Turning APOE4 into protective APOE2 or APOE3Christchurch to help with Alzheimer’s
A patient-facing explanation of a treatment idea that aims to change a genetic risk factor for Alzheimer's disease in the brain.
-
Telomerase in Alzheimer’s Disease: how aging biology could influence memory and brain health
Researchers are exploring a new brain-aging mechanism linked to telomerase, with potential to slow or modify Alzheimer’s disease in people and improve cognitive function.
-
Biomarkers of Alzheimer’s Disease: Sensory, Motor, and Cognitive Clues
Researchers are testing simple sensory and movement tasks to find early signs of Alzheimer’s disease so they can diagnose and treat people sooner.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.